Effect of XXXX on functional recovery in the spinal cord following @entity130 .

@entity35 @entity870 @entity205 @entity1566 @entity130
Considerable evidence has shown that the immunosuppressant drug @entity205 ( @entity870 ) may have neuroprotective properties which can be exploited in the treatment of @entity1566 . The aim of this study was to investigate the cellular environment within the spinal cord following injury and determine whether @entity870 has an effect on altering cellular interactions to promote a growth-permissive environment. @entity870 was administered to a group of @entity35 4 days after they endured a moderate @entity130 . Functional recovery was assessed using the Basso Beattie Bresnahan (BBB) locomotor rating scale at 3, 5 and 7 weeks post-injury. The @entity35 were sacrificed 3 and 7 weeks post-injury and the spinal cords were sectioned, stained using histological and immunohistochemical methods and analysed. Using stereology, the lesion size and cellular environment in the @entity870 -treated and control groups was examined. Little difference in lesion volume was observed between the two groups. An improvement in functional recovery was observed within @entity870 -treated animals at 3 weeks. Although we did not see significant reduction in tissue damage, there were some notable differences in the proportion of individual cells contributing to the lesion. @entity870 administration may be used as a technique to control the cell population of the lesion, making it more permissive to neuronal regeneration once the ideal environment for regeneration and the effects of @entity870 administration at different time points post-injury have been identified.
